Nucor earnings beat by $0.08, revenue fell short of estimates
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ) reported encouraging preclinical results for its hydrogel-based Trap & Target platform for intranasal drug delivery, according to a press release statement issued Thursday.
The study, conducted with the University of Parma in Italy, demonstrated that the company’s hydrogel formulation achieved targeted deposition in the upper regions of the nasal cavity, with over 60% accumulation in the middle and upper turbinates - areas considered favorable for nose-to-brain transport.
The research utilized a silicone-based human nasal cast and fluorescein-traced imaging to evaluate the delivery system’s performance. Professor Fabio Sonvico, a member of Polyrizon’s Scientific Advisory Board, led the collaborative study.
"The results validate the unique capabilities of our T&T technology in achieving localized deposition in anatomically favorable zones of the nasal cavity," said Tomer Izraeli, CEO at Polyrizon.
The company indicated this delivery method could potentially benefit central nervous system (CNS) indications such as opioid overdose treatment and benzodiazepine delivery for epileptic seizures, where rapid brain access is critical.
Polyrizon plans to further validate these findings in animal models and initiate safety studies as part of its development roadmap for the technology.
The biotechnology company specializes in developing intranasal drug delivery systems and is also working on a separate technology called Capture and Contain, which forms a protective barrier in the nasal cavity against viruses and allergens.
In other recent news, Polyrizon Ltd. has been notified by the Nasdaq Stock Market of a potential delisting due to actions that have resulted in significant dilution of its shareholders. The company plans to appeal this decision, which temporarily halts any suspension or delisting actions. Additionally, Polyrizon has initiated preclinical studies for an intranasal delivery method of Benzodiazepines, aimed at treating acute repetitive seizures, leveraging their hydrogel technology. The company also reported successful preliminary safety results for its PL-14 Allergy Blocker, which is designed to provide a barrier against allergens in the nasal cavity.
In a strategic move, Polyrizon has partnered with a branding consultancy to establish a brand identity for its Capture and Contain™ hydrogel technology, as it seeks to commercialize its products. Furthermore, Polyrizon has raised approximately $17 million through a private placement, with plans to use the proceeds for corporate purposes and working capital. The company’s ongoing developments underscore its commitment to advancing its clinical and regulatory milestones. These recent developments highlight Polyrizon’s efforts to innovate in the field of intranasal treatment solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.